MedTrace Logo

Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance

NCT02621060 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-08-02

Study results available
· View outcomes & findings →

Summary

Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others. The above mentioned findings show that Chlorogenic acid has an excellent potential for the control of glucose as well as insulin secretion and insulin sensitivity.

Conditions

  • Impaired Glucose Tolerance

Interventions

DRUG

Placebo

Placebo: 1200 mg per day for three months

DRUG

Chlorogenic acid

Chologenic acid: 1200 mg per day for three months

Sponsors & Collaborators

  • University of Guadalajara

    lead OTHER

Principal Investigators

  • Esperanza Martínez, PhD Science · University of Guadalajara

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-01-31
Completion
2016-02-29

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02621060 on ClinicalTrials.gov